BST-236(阿糖胞苷前药)治疗不适合标准化疗的急性白血病:1/2a期研究
该1/2a期剂量递增研究评估了新型阿糖胞苷前药BST-236在26例不适合标准诱导治疗的老龄或体弱急性白血病患者中的安全性、药代动力学和疗效。BST-236安全且耐受良好,最大耐受剂量为6 g/m2/天,总缓解率为29.6%;新诊断AML亚组(中位年龄78岁)的缓解率为45.5%,中位总生存期为6.5个月。
要点
- BST-236在老龄/不适合强化疗的急性白血病患者中安全耐受,最大耐受剂量为6 g/m2/天。
- 总体缓解率为29.6%,新诊断AML亚组缓解率达45.5%。
- 中位总生存期6.5个月,达到完全缓解的患者中位OS未达到。
核心结论
- BST-236可安全地向不适合标准诱导治疗的老龄患者递送高剂量阿糖胞苷并显示疗效。
研究设计与样本
- 1/2a期剂量递增研究,纳入26例不适合标准治疗的复发/难治或新诊断急性白血病患者。
- BST-236设6个剂量递增队列(0.3至6 g/m2/天),每日一次静脉输注60分钟,连续6天。
- 患者中位年龄76.5岁(范围26至90),84.6%的患者≥70岁。
主要发现
- BST-236安全且耐受良好,最大耐受剂量为6 g/m2/天。
- 总缓解率为29.6%。
- 新诊断AML(原发或继发于MDS)不适合标准诱导亚组(中位年龄78岁)的总体缓解率为45.5%。
- 中位总生存期为6.5个月,达到完全缓解的患者中位OS未达到。
临床怎么用
- 对于不适合标准诱导治疗的老龄或体弱急性白血病患者,BST-236可作为潜在的高剂量阿糖胞苷替代方案。
局限性
- 本研究为1/2a期小样本剂量递增研究,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose cytarabine is the backbone of acute myeloid leukemia (AML) treatment. Nevertheless, its use in older patients is considerably limited due to increased toxicity. BST-236 (INN aspacytarabine) is a novel cytarabine prodrug designed to deliver high-dose cytarabine to target cells with reduced systemic exposure to free cytarabine. This phase 1/2a dose-escalation study was designed to evaluate BST-236 safety, pharmacokinetics, and efficacy in older or unfit-for-intensive-therapy patients with acute leukemia. Twenty-six patients, unfit for standard therapy, who were either relapsed/refractory or newly diagnosed, received BST-236 in 6 dose-escalating cohorts (range 0.3 to 6 g/m2 per day). BST-236 was administered intravenously once daily over 60 minutes for 6 consecutive days. The median age was 76.5 (26 to 90), with 84.6% of patients ≥70 years. BST-236 was safe and well tolerated. The maximal tolerated dose was 6 g/m2 per day. Overall response rate was 29.6%. A subgroup analysis of newly diagnosed patients with AML, de novo or secondary to myelodysplastic syndrome, unfit for standard induction (median age 78), demonstrated overall response of 45.5%. The median overall survival was 6.5 months and was not reached in patients achieving complete remission. The findings of this phase 1/2 study suggest that BST-236 safely delivers high and efficacious cytarabine doses to older patients who are unfit for standard induction and lays the foundation for further studies of BST-236 in AML. This trial was registered at www.clinicaltrials.gov as #NCT02544438.
引用
- Zuckerman T, Ram R, Akria L, et al. BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study. Blood Adv. 2019. PMID: 31770437. doi:10.1182/bloodadvances.2019000468
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。